We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.17B
1-Year Est. Return 92.19%
This Fund
S&P 500
This Quarter Est. Return
+32.88%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$1.17B
AUM Growth
+$68.7M
Cap. Flow
+$9.42M
Cap. Flow %
0.81%
Top 10 Hldgs %
33.9%
Holding
116
New
34
Increased
23
Reduced
41
Closed
18

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$26.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$19M
3
MTD icon
Mettler-Toledo International
MTD
+$16.1M
4
MRK icon
Merck
MRK
+$14.9M
5
CYTK icon
Cytokinetics
CYTK
+$13.8M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$50M
2
LLY icon
Eli Lilly
LLY
+$27.1M
3
PEN icon
Penumbra
PEN
+$25.8M
4
GKOS icon
Glaukos
GKOS
+$23.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.83%
2 Miscellaneous 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$17.7B
$62.2M 5.34%
233,171
+81,137
+53% +$19M
AXSM icon
2
Axsome Therapeutics
AXSM
$10.8B
$53.8M 4.61%
219,596
-44,708
-17% -$9.7M
LLY icon
3
Eli Lilly
LLY
$1.02T
$47.1M 4.04%
39,258
-26,504
-40% -$27.1M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$16B
$38.7M 3.32%
160,768
-17,376
-10% -$3.81M
HUM icon
5
Humana
HUM
$48.2B
$37.5M 3.22%
+94,375
New +$26.9M
UNH icon
6
UnitedHealth
UNH
$356B
$36.7M 3.15%
88,276
+30,238
+52% +$11.2M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.8B
$36M 3.09%
213,407
-2,271
-1% -$337K
INBX icon
8
Inhibrx
INBX
$1.78B
$29.2M 2.51%
308,385
+2,954
+1% +$296K
UTHR icon
9
United Therapeutics
UTHR
$20.9B
$27.1M 2.32%
49,991
+10,186
+26% +$5.74M
RVMD icon
10
Revolution Medicines
RVMD
$45B
$26.8M 2.3%
143,222
+2,452
+2% +$358K
ICLR icon
11
Icon
ICLR
$12.7B
$23.7M 2.03%
136,482
+78,982
+137% +$10.1M
THC icon
12
Tenet Healthcare
THC
$21.3B
$23.7M 2.03%
126,572
-271,995
-68% -$50M
EW icon
13
Edwards Lifesciences
EW
$51.8B
$22.7M 1.94%
250,453
-4,057
-2% -$340K
WAT icon
14
Waters Corp
WAT
$40.2B
$22.4M 1.93%
59,825
+20,062
+50% +$6.84M
PEN icon
15
Penumbra
PEN
$12.7B
$19M 1.63%
60,221
-79,558
-57% -$25.8M
BBIO icon
16
BridgeBio Pharma
BBIO
$14.6B
$18.9M 1.62%
253,358
-4,389
-2% -$307K
SYK icon
17
Stryker
SYK
$116B
$17.8M 1.53%
56,637
+34,680
+158% +$10.9M
MTD icon
18
Mettler-Toledo International
MTD
$27B
$17M 1.46%
+13,344
New +$16.1M
INDV icon
19
Indivior Pharmaceuticals
INDV
$4.12B
$16.5M 1.41%
401,208
-173,458
-30% -$6.29M
MRK icon
20
Merck
MRK
$371B
$16.3M 1.4%
+127,118
New +$14.9M
CYTK icon
21
Cytokinetics
CYTK
$10.1B
$16.3M 1.4%
+191,686
New +$13.8M
LNTH icon
22
Lantheus
LNTH
$6.59B
$16.2M 1.39%
+146,403
New +$13.6M
CNC icon
23
Centene
CNC
$33.1B
$16M 1.37%
248,867
-14,619
-6% -$782K
COO icon
24
Cooper Companies
COO
$13.6B
$15.8M 1.36%
220,890
+51,061
+30% +$3.34M
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.5B
$15.7M 1.35%
29,313
-4,833
-14% -$2.48M
1
2 3 4 5

Similar funds

JC
Jacobs & Co San Francisco, California $1.17B AUM 37.3% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $1.16B AUM 40% 1-Year Est. Return
HCP
Hiddenite Capital Partners New York $1.16B AUM 95.58% 1-Year Est. Return
EC
Estate Counselors Thiensville, Wisconsin $1.16B AUM 21.97% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return
CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
VFP
Verus Financial Partners Richmond, Virginia $1.17B AUM 15.91% 1-Year Est. Return

PFM Health Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, PFM Health Sciences held 116 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q2 2026 filing shows 34 new, 23 increased, 41 reduced and 18 closed positions. Its largest new stake was Humana: 94,375 shares worth $37.5M. The largest sale was Tenet Healthcare, an estimated $50M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • PFM Health Sciences's largest Q2 2026 buy was Humana: 94,375 shares worth $37.5M.
  • PFM Health Sciences added most to Ascendis Pharma A/S in Q2 2026, an estimated $19M increase.
  • PFM Health Sciences's biggest Q2 2026 reduction was Tenet Healthcare, cutting an estimated $50M.
  • PFM Health Sciences fully exited Glaukos in Q2 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $1.17B portfolio in Q2 2026.
  • PFM Health Sciences opened 34 new positions and closed 18 in Q2 2026.
  • PFM Health Sciences's portfolio value rose 6.3% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.